These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 32015155)

  • 1. Targeting ATRX Loss through Inhibition of the Cell-Cycle Checkpoint Mediator WEE1.
    Cole KA
    Cancer Res; 2020 Feb; 80(3):375-376. PubMed ID: 32015155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of
    Liang J; Zhao H; Diplas BH; Liu S; Liu J; Wang D; Lu Y; Zhu Q; Wu J; Wang W; Yan H; Zeng YX; Wang X; Jiao Y
    Cancer Res; 2020 Feb; 80(3):510-523. PubMed ID: 31551363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition.
    Lewis CW; Bukhari AB; Xiao EJ; Choi WS; Smith JD; Homola E; Mackey JR; Campbell SD; Gamper AM; Chan GK
    Cancer Res; 2019 Dec; 79(23):5971-5985. PubMed ID: 31594837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity.
    Wright G; Golubeva V; Remsing Rix LL; Berndt N; Luo Y; Ward GA; Gray JE; Schonbrunn E; Lawrence HR; Monteiro ANA; Rix U
    ACS Chem Biol; 2017 Jul; 12(7):1883-1892. PubMed ID: 28557434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted inhibition of the WEE1 kinase as a novel therapeutic strategy in neuroendocrine neoplasms.
    Weindl L; Atreya I; Dietrich P; Neubeck S; Neurath MF; Pavel M
    Endocr Relat Cancer; 2021 Jul; 28(9):605-620. PubMed ID: 34128828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition.
    Chen X; Low KH; Alexander A; Jiang Y; Karakas C; Hess KR; Carey JPW; Bui TN; Vijayaraghavan S; Evans KW; Yi M; Ellis DC; Cheung KL; Ellis IO; Fu S; Meric-Bernstam F; Hunt KK; Keyomarsi K
    Clin Cancer Res; 2018 Dec; 24(24):6594-6610. PubMed ID: 30181387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
    Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
    Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma.
    Cole KA; Ijaz H; Surrey LF; Santi M; Liu X; Minard CG; Maris JM; Voss S; Reid JM; Fox E; Weigel BJ
    Cancer; 2023 Jul; 129(14):2245-2255. PubMed ID: 37081608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy.
    Matheson CJ; Casalvieri KA; Backos DS; Reigan P
    ChemMedChem; 2018 Aug; 13(16):1681-1694. PubMed ID: 29883531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy.
    Fu S; Wang Y; Keyomarsi K; Meric-Bernstam F; Meric-Bernstein F
    Expert Opin Investig Drugs; 2018 Sep; 27(9):741-751. PubMed ID: 30102076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress.
    Cuneo KC; Morgan MA; Davis MA; Parcels LA; Parcels J; Karnak D; Ryan C; Liu N; Maybaum J; Lawrence TS
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):782-90. PubMed ID: 26975930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting WEE1 Kinase in Cancer.
    Matheson CJ; Backos DS; Reigan P
    Trends Pharmacol Sci; 2016 Oct; 37(10):872-881. PubMed ID: 27427153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer.
    Geenen JJJ; Schellens JHM
    Clin Cancer Res; 2017 Aug; 23(16):4540-4544. PubMed ID: 28442503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells.
    Matheson CJ; Venkataraman S; Amani V; Harris PS; Backos DS; Donson AM; Wempe MF; Foreman NK; Vibhakar R; Reigan P
    ACS Chem Biol; 2016 Apr; 11(4):921-30. PubMed ID: 26745241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATRX and DAXX: Mechanisms and Mutations.
    Dyer MA; Qadeer ZA; Valle-Garcia D; Bernstein E
    Cold Spring Harb Perspect Med; 2017 Mar; 7(3):. PubMed ID: 28062559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance.
    Zheng H; Shao F; Martin S; Xu X; Deng CX
    Sci Rep; 2017 Mar; 7():43517. PubMed ID: 28262781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies.
    Oppel F; Tao T; Shi H; Ross KN; Zimmerman MW; He S; Tong G; Aster JC; Look AT
    PLoS Genet; 2019 Apr; 15(4):e1008039. PubMed ID: 30970016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting WEE1 in Pancreatic Cancer.
    Cancer Discov; 2019 Oct; 9(10):OF3. PubMed ID: 31471286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the WEE1 kinase as a molecular targeted therapy for gastric cancer.
    Kim HY; Cho Y; Kang H; Yim YS; Kim SJ; Song J; Chun KH
    Oncotarget; 2016 Aug; 7(31):49902-49916. PubMed ID: 27363019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.